In order to help and care for tuberculosis patients, Chinese Antituberculosis Association established the "Chinese Antituberculosis Foundation" in 2016, and jointly launched Chinese Antituberculosis Foundation----Tuberculosis Poor Assistance “Double1,000”Project by Fosun Foundation and Shenyang Hongqi Pharmaceutical Co., Ltd. (hereinafter referred to as the "Hongqi Pharma”) which was a member enterprise of Fosun Pharma in the theme promotional activity of World Tuberculosis Day in March.

On April 27, 2016 National Academic Conference was held by Chinese Antituberculosis Association in Zhuhai City, Guangdong Province, and the unveiling ceremony of Chinese Antituberculosis Foundation was also officially organized in the opening ceremony.

As a member unit of Chinese Antituberculosis Association and sponsor of Chinese Antituberculosis Foundation----Tuberculosis Poor Assistance “Double1,000”Project, Fosun Foundation, Fosun Pharma Group and its member enterprise Shenyang Hongqi Pharmaceutical Co., Ltd. (hereinafter referred to as the "Hongqi Pharma”) were invited to participate in the conference.

At the conference, Chinese Antituberculosis Association also branded Fosun Foundation and Hongqi Pharma with Sponsor of Chinese Antituberculosis Foundation----Tuberculosis Poor Assistance “Double1,000”Project. In addition, Vice-president of Fosun Pharma Group Wang Donghua and Hongqi pharma’s representative respectively made a speech.

The picture shows Vice-president of Fosun Pharma Wang Donghua and General Manager of Hongqi Pharma Yang Bo attended the unveiling ceremony of Sponsor of Chinese Antituberculosis Foundation----Tuberculosis Poor Assistance “Double1,000”Project awarded by Chinese Antituberculosis Association on behalf of Fosun Pharma.

“Double1,000”Project would exist from 2016 to 2020, for five years, and it could rescue at least 1,000 poor tuberculosis patients each year with each patient's fund of at least 1,000 yuan. Fosun Foundation, together with Fosun Pharma member enterprise Hongqi Pharma will continue to support the project through providing funds, medicines and other forms of sponsorship.

In Wang Donghua’s peech, he mentioned that Chinese Antituberculosis Foundation established by Chinese Antituberculosis Association and Chinese Antituberculosis Foundation---- Tuberculosis Poor Assistance “Double1,000”Project jointly launched by Fosun Foundation and Fosun Pharma member enterprise Hongqi Pharma were really joyous news to poor tuberculosis patients. They were also the conscious action for enterprises to thank the society in return. As a member of the health industry, we always focused on helping patients, especially poor patients to get timely relief, so that they would enjoy a healthy and happy life again. In future, we would continue to pay attention to and support Chinese Antituberculosis.

As the largest R&D base of antituberculosis drug, Hongqi Pharma made an important contribution to Chinese Antituberculosis. At present, the front-line antituberculosis drug included Rifampicin capsule, Rifampicin capsule II, Isoniazid Tablets, Ethambutol Tablets (capsules), Pyrazinamide tablets (capsules), Protionamide Enteric-coated Tablets, etc., whose sales were always in the forefront of the domestic market. Especially, FDC (Fixed Dose Combination) had two kinds of drugs respectively taken daily and every other day. At present, Hongqi Pharma produced series of antituberculosis drugs. Once a new pattern of antituberculosis system was established and upgraded, Hongqi Pharma would innovated more good products, making a greater contribution to Chinese Antituberculosis.